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In this study, adult volunteers were fed tcpA and mshA deletion mutants of V. cholerae O139 strain CVD 112
to determine the role of toxin-coregulated pili (TCP) and mannose-sensitive hemagglutinin (MSHA) in
intestinal colonization. Eight of 10 volunteers who received CVD 112 or CVD 112 DmshA shed the vaccine
strains in their stools; the geometric mean peak excretion for both groups was 1.4 3 105 CFU/g of stool. In
contrast, only one of nine recipients of CVD 112 DtcpA shed vibrios in his stool (P < 0.01); during the first 24 h
after inoculation, 3 3 102 CFU/g was recovered from this volunteer. All recipients of CVD 112 and 8 (80%) of
the recipients of CVD 112 DmshA developed at least a fourfold rise in vibriocidal titer after immunization. In
contrast, only one (11%) of the nine recipients of CVD 112 DtcpA developed a fourfold rise in vibriocidal titer
(P < 0.01). We conclude that TCP are an important colonization factor of V. cholerae O139 and probably of El
Tor V. cholerae O1. In contrast, MSHA does not appear to promote intestinal colonization in humans.
Adherence of Vibrio cholerae to the intestinal mucosa might
be mediated by different mechanisms, depending on the bio-
type (classical or El Tor) and serotype (O1 and O139). It is
clear that colonization of strains of V. cholerae O1 of the
classical biotype is mediated by toxin-coregulated pili (TCP),
which are encoded by tcpA (20). The importance of TCP in the
pathogenesis of cholera was demonstrated in volunteer studies.
Classical Ogawa V. cholerae O1 strain 395 with deletions in
tcpA did not cause diarrhea, did not colonize the duodenal
fluids or stools of volunteers, and did not induce vibriocidal or
antitoxic immune responses (6, 7).
The tcpA gene is also present in El Tor biotype V. cholerae
O1 strains (9, 16). In addition, most, if not all, strains of El Tor
V. cholerae O1 express another pilus, called mannose-sensitive
hemagglutinin (MSHA) (10). Mutations in tcpA and mshA
have been constructed, and the strains have been studied with
infant mice. The colonization of the mshA-deleted El Tor
V. cholerae O1 strain was no different from that of the wild
type; in contrast, the El Tor strain with deletions in tcpA was
markedly reduced in its ability to colonize infant mice (1, 2,
21).
The roles of these two pili in mediating protective immunity
have been studied with animals. Antibodies against classical
TCP have provided variable protection against V. cholerae El
Tor in mice (1, 15, 17, 18, 22). The inconsistent protection of
anti-TCP antibodies is likely explained by the sequence differ-
ences between El Tor and classical TCP; these proteins show
82% identity (16). The differences in protection mediated by
TCP antibodies may be due to the difference in the specificities
of anti-classical TCP serum and anti-El Tor TCP serum.
The mechanism of colonization of V. cholerae O139 has not
been established. V. cholerae O139 strains are closely related to
El Tor strains of the O1 group (3, 5, 8, 23), so one might expect
that colonization factors of El Tor O1 strains would also be
important in O139 strains. The gene for TCP pilin is present in
O139 strains, and the amino acid sequence is identical to that
of El Tor O1 strains (16). Mutants of V. cholerae O139 strain
M03 with deletions in tcpA and mshA have been constructed;
in colonization competition studies with the wild type, the tcpA
deletion mutant was markedly decreased in colonization (21).
In contrast, the DmshA mutant was somewhat better able to
compete for colonization of mice. In an independent study, an
O139 strain with deletions in mshA had no competitive advan-
tage (1). These data suggest that TCP are essential for the
colonization of infant mice with V. cholerae O139 and that
MSHA does not appear to have a significant role.
The purpose of this study was to determine the role of tcpA
and mshA in the intestinal colonization of volunteers given
V. cholerae O139 vaccine strain CVD 112 modified by deletions
in tcpA and mshA (designated strains KHT47 and KHT37,
respectively). CVD 112 is a derivative of V. cholerae O139
strain AI1837, designed as a vaccine candidate by deletions in
genes for cholera toxin A subunit (ctxA), zonula occludens
toxin, accessory cholera enterotoxin, and core encoded pilin,
which are on the bacteriophage CTXF (24). In the volunteer
study described here, we chose to use CVD 112 to avoid the
risks of dehydrating diarrhea in volunteers while still address-
ing questions about colonization.
MATERIALS AND METHODS
Clinical study design. Healthy adult volunteers were educated about cholera
and the requirements of the protocol, and informed, written consent was ob-
tained from each volunteer. Prospective volunteers were carefully screened to
ensure that they were in excellent physical and mental health. Screening con-
sisted of a medical history, physical examination, interview by a clinical psychol-
ogist, and a battery of blood tests.
A group of 29 inpatient volunteers was admitted to the research isolation
ward, located in the University of Maryland Hospital. They were randomized to
receive the following with sodium bicarbonate buffer: (i) 1 3 107 to 2 3 107 CFU
of V. cholerae O139 vaccine strain CVD 112 (n 5 10), (ii) 1 3 107 to 2 3 107 CFU
of V. cholerae O139 strain CVD 112 DtcpA (designated KHT47) (n 5 9), or (iii)
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1 3 107 to 2 3 107 CFU of V. cholerae O139 strain CVD 112 DmshA (designated
KHT37) (n 5 10).
Daily clinical observations were made in which symptoms were recorded.
Volunteers who developed diarrhea were given oral rehydration (with World
Health Organization glucose-electrolyte solution) after each loose stool. Volun-
teers were observed for 4 days and then treated with tetracycline (500 mg orally
every 6 h for four doses), followed by a single oral dose of doxycycline. They were
discharged from the isolation ward at day 7 after ingestion of vibrios.
From the time of admission, volunteers collected every bowel movement in
plastic containers. After collection of a stool, the contents of the stool container
were inspected and graded for consistency of the stool according to five grades:
grade 1, firm; grade 2, soft; grade 3, thick liquid; grade 4, opaque watery; and
grade 5, rice water. Grades 1 and 2 are variations of normal stools, while grades
3 to 5 are considered abnormal.
To culture vibrio from the proximal small intestine (the critical site of host-
bacterium interaction), volunteers ingested gelatin-encapsulated string devices
(Enterotest) approximately 20 and 44 h after ingestion of V. cholerae as previ-
ously described (7). Blood was collected before and 11 and 28 days after inges-
tion of vibrio for measurements of vibriocidal and anti-cholera toxin and anti-
TCP antibodies.
Preparation and administration of strains CVD 112, KHT47, and KHT37.
KHT47 and KHT37 were constructed as previously described (21). The strains
have no growth defect as determined by in vitro growth competition studies with
their lacZ-negative parent (21). The mutant strains and CVD 112 agglutinated
with anti-O139 antiserum to the same extent. The motilities of CVD 112,
KHT37, and KHT47 were normal and equivalent as assessed by motility agar
plates (Luria-Bertani agar containing 0.3% agar). The preparation of inocula for
administration to volunteers has been previously described (19). The strains were
administered orally with NaHCO3. Two grams of NaHCO3 was dissolved in 5 oz
(150 ml) of distilled water. Volunteers drank 4 oz of the NaHCO3 solution; 1 min
later, they ingested the vibrio strain suspended in the remaining 1 oz of NaHCO3
water. Volunteers had nothing to eat or drink for 90 min before and after
vaccination.
Definition of diarrhea. Diarrhea was defined as the passage of two or more
unformed (grades 3 to 5) stools over a 48-h period that equaled or exceeded
200 g or a single voluminous stool if it totaled 300 g or greater.
Bacteriology. All stools were plated directly onto thiosulfate-citrate-bile salts-
sucrose (TCBS) agar as well as inoculated into alkaline peptone water enrich-
ment broth for overnight incubation before being plated onto TCBS. Suspicious
colonies were agglutinated with specific antiserum. Up to three stools each day
were cultured quantitatively to determine the number of vibrios per gram of
stool.
Duodenal strings were tweezed with a sterile gloved hand to express duodenal
fluid. This was quantitatively cultured as described above as well as inoculated
directly onto TCBS. In addition, the strings were inoculated into alkaline pep-
tone water for overnight incubation before inoculation of plates of TCBS agar.
Immunology. Serum vibriocidal responses were determined against strain 2L,
the unencapsulated mutant of AI1837, the parent strain of CVD 112 (13).
Immunoglobulin G (IgG) antitoxin antibodies were measured by previously
described methods (12). TCP antibodies were also measured by enzyme-linked
immunosorbent assay as described previously (6) with purified TCP (18).
Statistical analysis. Rates of diarrhea and antibody conversion were compared
by Fisher’s exact tests. Comparisons of antibody titers were performed on log-
transformed reciprocal titers by Student’s t test.
RESULTS
Clinical and bacteriologic results. Mild diarrhea occurred in
3 (30%) of 10 recipients of 107 CFU of CVD 112, 5 (50%) of
10 recipients of 107 CFU of CVD 112 DmshA, and in none of
9 recipients of 107 CFU of CVD 112 DtcpA (Table 1). These
rates of diarrhea among recipients of CVD 112 and CVD 112
DmshA were similar to those previously observed among re-
cipients of similar doses of CVD 112 (24).
Eight of 10 volunteers who received CVD 112 or CVD 112
DmshA shed the vaccine strains in their stools; the geometric
mean peak excretion for both groups was 1.4 3 105 CFU/g of
stool (Table 1). This rate of shedding is similar to that observed
after ingestion of the wild-type parent strain, AI1837 (19). In
contrast, only one of nine recipients of CVD 112 DtcpA shed
vibrios in his stool (P , 0.01); during only the first 24 h after
inoculation, 3 3 102 CFU/g was recovered from this volunteer.
The duodenal fluid cultures gave a similar pattern (Table 1).
The numbers of organisms recovered from intestinal fluid were
similar in recipients of CVD 112 and CVD 112 DmshA (1.6 3
103 and 3.6 3 103, respectively).
Immune responses. V. cholerae O139 stimulates meager ti-
ters of vibriocidal antibodies after wild-type infection, com-
pared to the titers stimulated by V. cholerae O1, probably due
to the presence of the capsule on O139 strains (13, 14). All
recipients of CVD 112 and eight (80%) of the recipients of
TABLE 1. Clinical and bacteriologic responses in volunteers who received 107 CFU of V. cholerae O139 strain CVD 112,
KHT37 (CVD 112 DmshA), or KHT47 (CVD 112 DtcpA)
Strain Diarrhea attackratea (%)
Mean diarrheal
stool vol (ml)
Ratea of vibrio
excretion (%)
Geometric mean peak
no. of organisms/g
of stool
Ratea of positive
duodenal fluid
cultures (%)
Geometric mean no. of
organisms recovered
from duodenal fluid
CVD 112 3/10 (30) 693 8/10 (80) 1.4 3 105 3/8 (38) 1.6 3 103
KHT 37 (CVD 112 DmshA) 5/10 (50) 529 8/10 (80) 1.4 3 105 2/9 (22) 3.6 3 103
KHT47 (CVD 112 DtcpA) 0/9 (0)b 0 1/9 (11)c 3 3 102 0/7 (0)d 0
a Number with result/number tested.
b P 5 0.12 and 0.02 (Fisher’s exact tests) versus rates in CVD 112 and CVD 112 DmshA recipients, respectively.
c P , 0.01 (Fisher’s exact test) versus rates in CVD 112 and CVD 112 DmshA recipients.
d P is not significant (Fisher’s exact tests).
TABLE 2. Immune responses in volunteers who received 107 CFU of V. cholerae O139 strain CVD 112,
KHT37 (CVD 112 DmshA), or KHT47 (CVD 112 DtcpA)
Strain
Vibriocidala antibody
seroconversion
rateb (%)
Geometric mean peak
reciprocal vibriocidal
antibody titer
IgG anti-cholera toxin
antibody seroconver-
sion rateb (%)
Geometric mean change in
optical density for IgG anti-
cholera toxin antibody
IgG anti-TCP antibody
seroconversion
rateb (%)
CVD 112 10/10 (100) 121 10/10 (100) 0.78 2/10 (20)
KHT37 (CVD 112 DmshA) 8/10 (80) 106 8/10 (80) 0.63 1/10 (10)
KHT47 (CVD 112 DtcpA) 1/9 (11)c 29d 0/9 (0)e 0.04 0/9 (0)
a Vibriocidal responses were measured against V. cholerae O139 strain 2L, an encapsulated mutant of strain AI1837, the parent strain of CVD 112.
b Number with result/number tested.
c P , 0.01 (Fisher’s exact tests) versus rate in recipients of either CVD 112 or KHT37 (CVD 112 DmshA).
d P , 0.01 (Student’s t test) versus titer in recipients of either CVD 112 or KHT37 (CVD 112 DmshA).
e P , 0.001 (Fisher’s exact tests) versus rate in recipients of either CVD 112 or KHT37 (CVD 112 DmshA).
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CVD 112 DmshA developed a fourfold or greater rise in vibrio-
cidal titer after immunization; the geometric mean peak recip-
rocal titers were 121 and 106, respectively (Table 2). In con-
trast, only one (11%) of the nine recipients of CVD 112 DtcpA
developed a fourfold rise in vibriocidal titer (P , 0.01, Stu-
dent’s t tests comparing CVD 112 DtcpA responses to CVD 112
and CVD 112 DmshA responses). This volunteer was the one
who shed small numbers of CVD 112 DtcpA in his stool for 1
day. The vibriocidal response in this volunteer was unusual,
since it occurred on day 28 after vaccination and was not
present on day 11 after vaccination, when the amount of vibrio-
cidal antibody in U.S. volunteers usually peaks (4). None of the
recipients of CVD 112 DtcpA developed anti-cholera toxin
antibody, while all of the recipients of CVD 112 and 80% of
the recipients of CVD 112 DmshA developed anti-cholera
toxin antibody (P , 0.001, Fisher’s exact tests, comparing CVD
112 DtcpA to either of the other two groups). IgG antibodies
against TCP were detected in 2 of 10 recipients of CVD 112, 1
of 10 recipients of CVD 112 DmshA, and none of the recipients
of CVD 112 DtcpA.
DISCUSSION
This clinical study clearly demonstrates the importance of
TCP expression for V. cholerae O139 to colonize the intestine,
cause diarrhea, and stimulate immune responses. Deletion in
tcpA resulted in the absence of diarrhea and marked decrease
in colonization and immune responses in volunteers. Deletion
in mshA had no effect on the attack rate of diarrhea, the
volume of diarrheal stool, or the numbers of vibrios recovered
in duodenal fluid or stool. Our data suggest that MSHA is not
necessary for colonization, and a role for MSHA in producing
mild diarrhea associated with CVD 112 could not be demon-
strated.
V. cholerae O139 is strikingly similar to biotype El Tor
V. cholerae O1 and probably evolved recently from an El Tor
strain (3, 5, 8). Although O139 strains express a polysaccharide
capsule and have an altered lipopolysaccharide, they are sim-
ilar to El Tor O1 strains by DNA sequences of crucial virulence
factors and by multilocus enzyme electrophoresis. It is likely,
therefore, that TCP are the critical colonization factor for El
Tor O1, as they are for classical O1 strains (7).
This study emphasizes the importance of colonization for
stimulating an immune response to V. cholerae. This finding
has implications for the development of live attenuated vaccine
strains, which should express TCP, and killed-whole-cell vac-
cines, which should contain TCP on the surfaces of classical
and El Tor components, to stimulate protective immune re-
sponses. The very low (11%) vibriocidal seroconversion rate
among recipients of KHT47 (DtcpA) demonstrates that
V. cholerae must express this antigen to stimulate serum vibrio-
cidal antibodies, the best immune correlate of protection
against cholera. These data also support the possibility that in
humans, like in animals, strong mucosal immunity against the
single antigen TCP could be adequate for protection against
cholera by interfering with colonization and diarrheagenicity.
Protection against another toxigenic enteric pathogen, Esche-
richia coli, appears to be mediated by anti-colonization factor
responses (11). However, unlike E. coli colonization factors,
TCP are only weakly immunogenic in humans after infection
with live V. cholerae O1 (6) and after vaccination with O139
strain CVD 112, and so anti-TCP responses do not participate
in natural immunity. It is possible that an immune response to
TCP could be stimulated by presenting this antigen to mucosal
immune sites with an appropriate carrier or with a mucosal
adjuvant.
TCP have another function in bacterial physiology: the pilus
is the receptor for a filamentous bacteriophage, CTXF, which
encodes V. cholerae toxins (24). This surface structure, then, is
possibly the ultimate virulence factor of V. cholerae, since TCP
mediate infection of the bacterium with the phage, which in
turn encodes cholera toxin, the factor responsible for cholera
gravis. Our study shows that, without TCP, V. cholerae is thor-
oughly disarmed.
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